BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34670169)

  • 1. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
    Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
    Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
    Armand P; Chen YB; Redd RA; Joyce RM; Bsat J; Jeter E; Merryman RW; Coleman KC; Dahi PB; Nieto Y; LaCasce AS; Fisher DC; Ng SY; Odejide OO; Freedman AS; Kim AI; Crombie JL; Jacobson CA; Jacobsen ED; Wong JL; Patel SS; Ritz J; Rodig SJ; Shipp MA; Herrera AF
    Blood; 2019 Jul; 134(1):22-29. PubMed ID: 30952672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab for the treatment of Hodgkin Lymphoma.
    Al Hadidi SA; Lee HJ
    Expert Opin Biol Ther; 2020 Nov; 20(11):1275-1282. PubMed ID: 33006479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
    Merrill MH; Dahi PB; Redd RA; McDonough MM; Chen YB; DeFilipp Z; Herrera AF; Fisher DC; LaCasce AS; Odejide OO; Ng SY; Jacobson CA; Merryman RW; Kim AI; Nieto YL; Sauter CS; Shah GL; Zain JM; Armand P; Jacobsen ED
    Blood; 2023 Aug; 142(7):621-628. PubMed ID: 37319432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells.
    Landsburg DJ; Nasta SD; Svoboda J; Gerson JN; Schuster SJ; Barta SK; Chong EA; Difilippo H; Weber E; Cunningham K; Catania C; Garfall AL; Stadtmauer EA; Frey NV; Porter DL
    Transplant Cell Ther; 2023 Aug; 29(8):495-503. PubMed ID: 37211154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.
    Frigault MJ; Armand P; Redd RA; Jeter E; Merryman RW; Coleman KC; Herrera AF; Dahi P; Nieto Y; LaCasce AS; Fisher DC; Ng SY; Odejide OO; Freedman AS; Kim AI; Crombie JL; Jacobson CA; Jacobsen ED; Wong JL; Bsat J; Patel SS; Ritz J; Rodig SJ; Shipp MA; Chen YB; Joyce RM
    Blood Adv; 2020 Jan; 4(1):122-126. PubMed ID: 31917843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
    Merryman RW; Redd RA; Taranto E; Ahmed G; Jeter E; McHugh KM; Brown JR; Crombie JL; Davids MS; Fisher DC; Freedman AS; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Jacene H; Park H; Dahi PB; Nieto Y; Joyce RM; Chen YB; Shipp MA; Herrera AF; Armand P
    Blood Adv; 2023 Sep; 7(17):4748-4759. PubMed ID: 36399518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
    Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
    Merryman RW; Redd RA; Nishihori T; Chavez J; Nieto Y; Darrah JM; Rao U; Byrne MT; Bond DA; Maddocks KJ; Spinner MA; Advani RH; Ballard HJ; Svoboda J; Singh AK; McGuirk JP; Modi D; Ramchandren R; Romancik J; Cohen JB; Frigault MJ; Chen YB; Serritella AV; Kline J; Ansell S; Nathan S; Rahimian M; Joyce RM; Shah M; David KA; Park S; Beaven AW; Habib A; Bachanova V; Nakhoda S; Khan N; Lynch RC; Smith SD; Ho VT; LaCasce A; Armand P; Herrera AF
    Blood Adv; 2021 Mar; 5(6):1648-1659. PubMed ID: 33710337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
    Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
    Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma.
    Zhang C; Deng J; Xie Y; Mi L; Liu W; Wang X; Zhao L; Song Y; Zhu J
    Cancer Med; 2023 May; 12(9):10351-10362. PubMed ID: 37081731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
    Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
    Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
    Armand P; Zinzani PL; Lee HJ; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Herrera AF; Lin J; Kim E; Chakraborty S; Marinello P; Moskowitz CH
    Blood; 2023 Sep; 142(10):878-886. PubMed ID: 37319435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
    Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
    Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
    Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
    J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.
    Liu Y; Ping L; Song Y; Tang Y; Zheng W; Liu W; Ying Z; Zhang C; Wu M; Feng F; Lin N; Tu M; Zhu J; Xie Y
    BMC Med; 2024 Mar; 22(1):107. PubMed ID: 38454451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
    Ferreri AJ; Sassone M; Zaja F; Re A; Spina M; Rocco AD; Fabbri A; Stelitano C; Frezzato M; Rusconi C; Zambello R; Couto S; Ren Y; Arcari A; Bertoldero G; Nonis A; Scarfò L; Calimeri T; Cecchetti C; Chiozzotto M; Govi S; Ponzoni M
    Lancet Haematol; 2017 Mar; 4(3):e137-e146. PubMed ID: 28219694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
    Lee L; Alrasheed N; Khandelwal G; Fitzsimons E; Richards H; Wilson W; Chavda SJ; Henry J; Conde L; De Massy MR; Chin M; Galas-Filipowicz D; Herrero J; Chain B; Quezada SA; Yong K
    Front Immunol; 2021; 12():618610. PubMed ID: 33717112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
    Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F
    Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.